Market Overview

UPDATE: Stifel Nicolaus Initiates Align Technology at Buy on EPS Reacceleration

Related ALGN
Medical Device Co. Align Technology Has Clear Upside, Says Leerink
Trial Date Set For Traders Accused Of $100 Million Hacking Scheme

Stifel Nicolaus initiated coverage on Align Technology (NASDAQ: ALGN) with a Buy rating and a $32 price target.

Stifel Nicolaus commented, "Admittedly, EPS growth is likely to be suppressed in 1H13 due to difficult comps and near-term spend (purchase of APAC distributor). However, we expect a quick payoff on the investments and point to our estimated 2H13 y/y EPS growth of 40%. Once investors get comfortable that EPS is poised to meaningfully accelerate, multiple expansion will quickly follow. Despite the 3Q12 earnings disappointment, we believe Align's fundamentals remain intact. Specifically, our doctor diligence points to the potential for 2013 case volume upside, competition continues to flounder and Align's cash flow remains strong (YE net cash per share of $6)."

Align Technology closed at $26.03 on Wednesday.

Latest Ratings for ALGN

Jul 2015Stifel NicolausMaintainsBuy
Apr 2015Morgan StanleyUpgradesEqual-weightOverweight
Jan 2015JMP SecuritiesDowngradesMarket OutperformMarket Perform

View More Analyst Ratings for ALGN
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (ALGN)

Get Benzinga's Newsletters